Equities research analysts expect that Amedisys Inc (NASDAQ:AMED) will post earnings per share of $0.93 for the current quarter, Zacks reports. Seven analysts have issued estimates for Amedisys’ earnings. The highest EPS estimate is $1.01 and the lowest is $0.88. Amedisys posted earnings of $0.91 per share in the same quarter last year, which suggests a positive year over year growth rate of 2.2%. The firm is expected to announce its next quarterly earnings results on Wednesday, February 26th.

According to Zacks, analysts expect that Amedisys will report full year earnings of $4.39 per share for the current financial year, with EPS estimates ranging from $4.35 to $4.47. For the next financial year, analysts forecast that the firm will post earnings of $4.85 per share, with EPS estimates ranging from $4.50 to $5.37. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Amedisys.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Tuesday, October 29th. The health services provider reported $1.15 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.90 by $0.25. Amedisys had a net margin of 6.70% and a return on equity of 26.53%. The company had revenue of $494.63 million during the quarter, compared to the consensus estimate of $494.14 million. During the same period in the prior year, the firm earned $0.95 earnings per share. Amedisys’s revenue was up 18.5% on a year-over-year basis.

A number of equities analysts recently issued reports on AMED shares. Barclays increased their price target on shares of Amedisys from $120.00 to $125.00 and gave the stock an “equal weight” rating in a research note on Monday, August 5th. ValuEngine downgraded shares of Amedisys from a “buy” rating to a “hold” rating in a research note on Thursday, September 26th. Robert W. Baird raised shares of Amedisys from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $140.00 to $160.00 in a research note on Friday, November 1st. Deutsche Bank started coverage on shares of Amedisys in a research note on Monday, September 16th. They issued a “buy” rating and a $155.00 price target for the company. Finally, Stephens reissued an “equal weight” rating and issued a $145.00 price target on shares of Amedisys in a research note on Tuesday, October 22nd. Five analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Amedisys presently has a consensus rating of “Buy” and a consensus target price of $147.20.

In other Amedisys news, Director Donald A. Washburn sold 8,667 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $149.96, for a total transaction of $1,299,703.32. Following the completion of the transaction, the director now owns 36,698 shares of the company’s stock, valued at $5,503,232.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Christopher Gerard sold 350 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $128.79, for a total transaction of $45,076.50. Following the transaction, the chief operating officer now directly owns 25,239 shares of the company’s stock, valued at approximately $3,250,530.81. The disclosure for this sale can be found here. Insiders have sold 18,407 shares of company stock valued at $2,694,756 in the last ninety days. Insiders own 2.90% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in AMED. Maverick Capital Ltd. grew its holdings in shares of Amedisys by 8,095.3% during the third quarter. Maverick Capital Ltd. now owns 36,715 shares of the health services provider’s stock valued at $4,810,000 after buying an additional 36,267 shares during the last quarter. Metropolitan Life Insurance Co NY grew its holdings in shares of Amedisys by 13.3% during the third quarter. Metropolitan Life Insurance Co NY now owns 18,345 shares of the health services provider’s stock valued at $2,403,000 after buying an additional 2,152 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Amedisys by 125.2% during the third quarter. Millennium Management LLC now owns 26,099 shares of the health services provider’s stock valued at $3,419,000 after buying an additional 14,512 shares during the last quarter. Squarepoint Ops LLC grew its holdings in shares of Amedisys by 4.1% during the third quarter. Squarepoint Ops LLC now owns 32,597 shares of the health services provider’s stock valued at $4,271,000 after buying an additional 1,296 shares during the last quarter. Finally, Public Employees Retirement System of Ohio grew its holdings in shares of Amedisys by 2.6% during the third quarter. Public Employees Retirement System of Ohio now owns 6,940 shares of the health services provider’s stock valued at $909,000 after buying an additional 176 shares during the last quarter. 90.90% of the stock is owned by institutional investors and hedge funds.

AMED stock traded down $0.57 during trading on Monday, reaching $162.39. The company had a trading volume of 240,105 shares, compared to its average volume of 366,675. Amedisys has a 52 week low of $103.76 and a 52 week high of $165.73. The company has a market cap of $5.26 billion, a P/E ratio of 44.74, a PEG ratio of 2.26 and a beta of 1.47. The business has a 50 day moving average of $144.60 and a 200 day moving average of $129.92. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.95 and a quick ratio of 0.95.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Featured Article: Call Option

Get a free copy of the Zacks research report on Amedisys (AMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.